Drugs and Chemicals of
Concern > N-Benzylpiperazine
N-BENZYLPIPERAZINE
(Street Names: BZP, A2, Legal E or Legal X)
August 2007
DEA/OD/ODE
Introduction:
N-Benzylpiperazine (BZP) was first
synthesized in 1944 as a potential antiparasitic agent. It was subsequently
shown to possess antidepressant activity and amphetamine-like effects, but was
not developed for marketing. The amphetamine-like effects of BZP attracted the
attention of drug abusers. Since 1996, BZP has been abused by drug abusers; as
evidenced by the encounters of this substance by law enforcement officials in
various states and the District of Columbia. The Drug Enforcement
Administration (DEA) placed BZP in schedule I of the Controlled Substances Act
(CSA) because of its high abuse potential and lack of accepted medical use or
safety.
Licit Uses:
BZP is used as an intermediate in
chemical synthesis. It has no known medical use in the United States.
Chemistry and Pharmacology:
BZP is an N-monosubstituted piperazine
derivative available as either base or the hydrochloride salt. The base form
is a slightly yellowish-green liquid. The hydrochloride salt is a white solid.
BZP base is corrosive and causes burns. The salt form of BZP is an irritant to
eyes, respiratory system and skin.
Both animal studies and human clinical
studies have demonstrated that the pharmacological effects of BZP are
qualitatively similar to those of amphetamine. BZP has been reported to be
similar to amphetamine in its effects on chemical transmission in brain. BZP
fully mimics discriminative stimulus effects of amphetamine in animals. BZP is
self-administered by monkeys indicating reinforcing effects. Subjective
effects of BZP were amphetamine-like in drug-naive volunteers and in
volunteers with a history of stimulant dependence. BZP acts as a stimulant in
humans and produces euphoria and cardiovascular effects, namely increases in
heart rate and systolic blood pressure. BZP is about 10 to 20 times less
potent than amphetamine in producing these effects. Experimental studies
demonstrate that the abuse, dependence potential, pharmacology and toxicology
of BZP are similar to those of amphetamine. Public health risks of BZP are
similar to those of amphetamine.
Illicit Uses:
BZP is often taken in combination with
1-[3-(trifluoro-methyl)phenyl]piperazine (TFMPP), a noncontrolled substance,
in order to enhance its spectrum of effects and has been promoted to youth
population as substitute for MDMA at raves (all-night dance parties). It may
also be abused alone for its stimulant effects. BZP is generally administered
orally as either powder or tablets and capsules. Other routes of
administration included smoking and snorting. In 2001, a report from
University in Zurich, Switzerland described the death of a young female which
was attributed to the combined use of BZP and MDMA.
User Population:
Youth and young adults are the main
abusers of BZP.
Illicit Distribution:
According to STRIDE and NFLIS, BZP has
been encountered in a number of states including Alabama, Arizona, Arkansas,
California, Colorado, Connecticut, District of Columbia, Florida, Georgia,
Illinois, Indiana, Louisiana, Maryland, Massachusetts, Maine, Michigan,
Minnesota, Missouri, Mississippi, North Carolina, Nevada, New Jersey, New
Mexico, New York, Ohio, Oregon, Pennsylvania, South Carolina, Texas, Virginia,
Washington, and Wisconsin.
Since 2001, according to the System to
Retrieve Information from Drug Evidence (STRIDE) database, DEA forensic
laboratories analyzed 128 drug exhibits from 59 law enforcement cases
pertaining to the trafficking, distribution and abuse of BZP. The analyzed
drug exhibits comprised of 66,645 tablets, 8,409 capsules and 356,997.1 grams
of powder.
According to the National Forensic
Laboratory Information System (NFLIS), state and local forensic laboratories
analyzed 94 BZP drug items from 76 law enforcement cases during 2000 through
2006.
Illicit distributions occur through
smuggling of bulk powder through drug trafficking organizations with
connections to oversea sources of supply. The bulk powder is then processed
into capsules and tablet. BZP is encountered as pink, white, off-white,
purple, orange, tan, and mottle orange-brown tablets. These tablets bear
imprints commonly seen on MDMA tablets such as housefly, crown, heart,
butterfly, smiley face or bull’s head logos and are often sold as
"ecstasy." BZP has been found in powder or liquid form which is
packaged in small convenience sizes and sold on the Internet.
Control Status:
BZP was temporarily placed into schedule
I of the CSA on September 20, 2002 (67 FR 59161). On March 18, 2004, the DEA
published a Final Rule in the Federal Register permanently placing BZP in
schedule I.
Comments and
additional information are welcomed by the Drug and Chemical
Evaluation Section, FAX 202-353-1263 or telephone 202-307-7183.
|